(4 years, 11 months ago)
Commons ChamberThis country will always stand up for the rule of law in Yemen, in Saudi Arabia and throughout the middle east. I hope very much that the hon. Gentleman understands that this country is the champion of international humanitarian law, especially in relation to Yemen, where he knows full well we are the pen holder. In my recent visit to the middle east, including to discuss Yemen, that came across loud and clear; I made it clear to my interlocutors that we will continue to hold them to account for activities in Yemen.
My hon. Friend is absolutely right and will know that the 2016 London anti-corruption summit agreed new commitments on ownership transparency. He will also be aware of the leadership we have shown on things like beneficial ownership, unexplained wealth orders, the seizure of criminals’ money from bank accounts and new powers to tackle onshore and offshore tax evasion. The UK is absolutely at the forefront of tackling these things and my hon. Friend is right to draw attention to that.
(5 years, 2 months ago)
Commons ChamberAntimicrobial resistance is a major global health threat and tackling it is a UK priority. DFID works alongside the Department of Health and Social Care and other Departments to support research on and development of new antimicrobials and diagnostic tools and to reduce the need for antimicrobials by preventing infection and enabling prompt diagnosis and treatment.
The O’Neill review makes the case that high-income countries should help low-income countries do important mitigation works in this area, with one example being reducing pollution from pharmaceutical production facilities that give rise to superbugs, which can travel round the world, including to the UK. Will my right hon. Friend outline the work we are carrying out in this area?
Yes, but before doing so, I wish to pay tribute to my hon. Friend’s work and interest in this area. He may be familiar with this, but I would like to draw his attention to the Access to Medicine Foundation, which is jointly funded by DFID, the Dutch Government and the Gates Foundation. It focuses on low-income and middle-income countries, and I particularly draw his attention to its antimicrobial resistance benchmark of 30 pharmaceutical companies, which prompts the pharmaceutical industry to do much more to bring AMR under control, including by reducing pharmaceutical pollution from the undertakings it operates.